BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17938224)

  • 1. Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1.
    Faber BW; Remarque EJ; Morgan WD; Kocken CH; Holder AA; Thomas AW
    Infect Immun; 2007 Dec; 75(12):5947-55. PubMed ID: 17938224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a chimeric Plasmodium falciparum merozoite surface protein vaccine in Aotus monkeys.
    Burns JM; Miura K; Sullivan J; Long CA; Barnwell JW
    Malar J; 2016 Mar; 15():159. PubMed ID: 26975721
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A diversity-covering approach to immunization with Plasmodium falciparum apical membrane antigen 1 induces broader allelic recognition and growth inhibition responses in rabbits.
    Remarque EJ; Faber BW; Kocken CH; Thomas AW
    Infect Immun; 2008 Jun; 76(6):2660-70. PubMed ID: 18378635
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1 randomized controlled trial to evaluate the safety and immunogenicity of recombinant Pichia pastoris-expressed Plasmodium falciparum apical membrane antigen 1 (PfAMA1-FVO [25-545]) in healthy Malian adults in Bandiagara.
    Thera MA; Coulibaly D; Kone AK; Guindo AB; Traore K; Sall AH; Diarra I; Daou M; Traore IM; Tolo Y; Sissoko M; Niangaly A; Arama C; Baby M; Kouriba B; Sissoko MS; Sagara I; Toure OB; Dolo A; Diallo DA; Remarque E; Chilengi R; Noor R; Sesay S; Thomas A; Kocken CH; Faber BW; Imoukhuede EB; Leroy O; Doumbo OK
    Malar J; 2016 Aug; 15(1):442. PubMed ID: 27577237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.
    Miura K; Zhou H; Diouf A; Moretz SE; Fay MP; Miller LH; Martin LB; Pierce MA; Ellis RD; Mullen GE; Long CA
    Clin Vaccine Immunol; 2009 Jul; 16(7):963-8. PubMed ID: 19439523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diversity covering AMA1-MSP119 fusion proteins as malaria vaccines.
    Faber BW; Younis S; Remarque EJ; Rodriguez Garcia R; Riasat V; Walraven V; van der Werff N; van der Eijk M; Cavanagh DR; Holder AA; Thomas AW; Kocken CH
    Infect Immun; 2013 May; 81(5):1479-90. PubMed ID: 23429538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.
    Elias SC; Collins KA; Halstead FD; Choudhary P; Bliss CM; Ewer KJ; Sheehy SH; Duncan CJ; Biswas S; Hill AV; Draper SJ
    J Immunol; 2013 Feb; 190(3):1135-47. PubMed ID: 23293353
    [TBL] [Abstract][Full Text] [Related]  

  • 8. posttranslational modification of recombinant Plasmodium falciparum apical membrane antigen 1: impact on functional immune responses to a malaria vaccine candidate.
    Giersing B; Miura K; Shimp R; Wang J; Zhou H; Orcutt A; Stowers A; Saul A; Miller LH; Long C; Singh S
    Infect Immun; 2005 Jul; 73(7):3963-70. PubMed ID: 15972483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.
    Bruder JT; Stefaniak ME; Patterson NB; Chen P; Konovalova S; Limbach K; Campo JJ; Ettyreddy D; Li S; Dubovsky F; Richie TL; King CR; Long CA; Doolan DL
    Vaccine; 2010 Apr; 28(18):3201-10. PubMed ID: 20188680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
    Lalitha PV; Biswas S; Pillai CR; Saxena RK
    Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion.
    Kocken CH; Withers-Martinez C; Dubbeld MA; van der Wel A; Hackett F; Valderrama A; Blackman MJ; Thomas AW
    Infect Immun; 2002 Aug; 70(8):4471-6. PubMed ID: 12117958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overcoming allelic specificity by immunization with five allelic forms of Plasmodium falciparum apical membrane antigen 1.
    Miura K; Herrera R; Diouf A; Zhou H; Mu J; Hu Z; MacDonald NJ; Reiter K; Nguyen V; Shimp RL; Singh K; Narum DL; Long CA; Miller LH
    Infect Immun; 2013 May; 81(5):1491-501. PubMed ID: 23429537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.
    Kennedy MC; Wang J; Zhang Y; Miles AP; Chitsaz F; Saul A; Long CA; Miller LH; Stowers AW
    Infect Immun; 2002 Dec; 70(12):6948-60. PubMed ID: 12438374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antigenicity of a Bacterially Expressed Triple Chimeric Antigen of Plasmodium falciparum AARP, MSP-311 and MSP-119: PfAMSP-Fu35.
    Kalra A; Edula JR; Gupta PK; Pandey AK; Chauhan VS
    PLoS One; 2016; 11(10):e0165720. PubMed ID: 27798691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Humoral immune responses to a single allele PfAMA1 vaccine in healthy malaria-naïve adults.
    Remarque EJ; Roestenberg M; Younis S; Walraven V; van der Werff N; Faber BW; Leroy O; Sauerwein R; Kocken CH; Thomas AW
    PLoS One; 2012; 7(6):e38898. PubMed ID: 22768052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fusion of two malaria vaccine candidate antigens enhances product yield, immunogenicity, and antibody-mediated inhibition of parasite growth in vitro.
    Pan W; Huang D; Zhang Q; Qu L; Zhang D; Zhang X; Xue X; Qian F
    J Immunol; 2004 May; 172(10):6167-74. PubMed ID: 15128804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability and potency of the Plasmodium falciparum MSP1-19/AMA-1(III) chimeric vaccine candidate with Montanide ISA720 adjuvant.
    Xue X; Ding F; Zhang Q; Pan X; Qu L; Pan W
    Vaccine; 2010 Apr; 28(18):3152-8. PubMed ID: 20197139
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In immunization with Plasmodium falciparum apical membrane antigen 1, the specificity of antibodies depends on the species immunized.
    Miura K; Zhou H; Muratova OV; Orcutt AC; Giersing B; Miller LH; Long CA
    Infect Immun; 2007 Dec; 75(12):5827-36. PubMed ID: 17923516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.
    Kusi KA; Faber BW; Thomas AW; Remarque EJ
    PLoS One; 2009 Dec; 4(12):e8110. PubMed ID: 19956619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1
    Rocha MV; Françoso KS; Lima LC; Camargo TM; Machado RLD; Costa FTM; Rénia L; Nosten F; Russell B; Rodrigues MM; Soares IS
    Vaccine; 2017 Apr; 35(18):2463-2472. PubMed ID: 28341111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.